SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

Reimbursement

Are your PNH patients uninsured or underinsured or having difficulties achieving reimbursement from their third-party payor? Assistance is available for patients who qualify. Learn more.

Reimbursement for SOLIRIS treatment

Reimbursement
click to enlarge

Reimbursement for SOLIRIS® (eculizumab) and drug administration services will vary by payor and by treatment setting, as outlined in the table.

For more information about reimbursement, contact an Alexion Case Manager by calling 1.888.SOLIRIS (1.888.765.4747].

Next: Patient Assistance

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.